Telix Pharmaceuticals Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLPPF research report →
Companytelixpharma.com
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases.
- CEO
- Christian Behrenbruch
- IPO
- 2019
- Employees
- 415
- HQ
- North Melbourne, VIC, AU
Price Chart
Valuation
- Market Cap
- $3.30B
- P/E
- -441.17
- P/S
- 3.91
- P/B
- 7.69
- EV/EBITDA
- 144.60
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 50.76%
- Op Margin
- 2.11%
- Net Margin
- -0.89%
- ROE
- -2.08%
- ROIC
- 1.77%
Growth & Income
- Revenue
- $1.25B · 59.10%
- Net Income
- $-11,045,359 · -122.13%
- EPS
- $-0.03 · -121.80%
- Op Income
- $27.54M
- FCF YoY
- -1051.28%
Performance & Tape
- 52W High
- $17.50
- 52W Low
- $5.91
- 50D MA
- $9.74
- 200D MA
- $9.07
- Beta
- 0.65
- Avg Volume
- 2.61K
Get TickerSpark's AI analysis on TLPPF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TLPPF Coverage
We haven't published any research on TLPPF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TLPPF Report →